Stocktoria

ELITE PHARMACEUTICALS INC /NV/ ELTP

OTC · stock · Pharmaceutical Preparations · website · IPO 2014-02-20

ELITE PHARMACEUTICALS INC /NV/ (ELTP) earns a Piotroski F-score of 6/9 (mixed financial health), with an Altman Z″ in the safe zone. It does not currently pay a dividend. FY2026 revenue was $148.9M at a 30.1% net margin.

$0.69 high · $0.34 low · daily closes (~2y) · hover for date & price
88/100
Stocktoria Quality Score · grade A+
6/9
Piotroski F — financial health
7.73
Altman Z″ — distress risk · safe
Dividend yield · no dividend
-1.08
Beneish M-score — earnings quality · elevated

Quality score trend · recomputed for each fiscal year

Piotroski F /9
3 2 2 4 7 5 3 3 5 6 2017201820192020202120222023202420252026
Altman Z″
-8.64 -14.80 -19.53 -14.71 -7.08 -5.54 0.76 1.72 7.73 2017201820192020202120222023202420252026

Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.

$0.36 as of 2026-08-01 · -47.8% 1y
$0.34$0.6952-wk

Beneish M-score: -1.08 — elevated (above the −1.78 line — aggressive-accounting signals worth a closer look) . A statistical screen for earnings manipulation, not proof — and it doesn't apply to most banks/insurers.

Market cap USD$425M
P / E9.5×
Net margin 5y avg19.7%
Revenue trend · last 10y · up

How it ranks in Manufacturing · percentile among 1961 companies

Piotroski Fstronger than 78%
Net marginstronger than 96%
Return on equitystronger than 97%
Revenue growthstronger than 96%

Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.

Piotroski F breakdown · 6/9 tests passed

Altman Z″ components · safe zone

ComponentValue
Working capital / assets0.685
Retained earnings / assets-0.548
EBIT / assets0.355
Equity / liabilities2.509

Sector peers · similar-size Manufacturing companies compare side by side →

TickerCompanyPiotroski FAltman Z″P / ERevenue growth
ELTPELITE PHARMACEUTICALS INC /NV/6/97.739.5+77.1%
MGNXMACROGENICS INC2/9-12.89-0.3%
KPTIKaryopharm Therapeutics Inc.2/9+0.6%
HRTXHERON THERAPEUTICS, INC. /DE/2/9+7.4%
LQDALiquidia Corp3/9-4.36+1031.2%
LFCRLIFECORE BIOMEDICAL, INC. \DE\3/9-1.75+0.5%
XNCRXencor Inc3/92.23+13.7%

All Manufacturing companies →

About ELITE PHARMACEUTICALS INC /NV/

Elite Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development, manufacture, and sale of oral, controlled-release products, and generic pharmaceuticals. The company operates through Abbreviated New Drug Applications for Generic Pharmaceuticals and New Drug Applications for Branded Pharmaceuticals segments. It owns, licenses, manufactures, and sales of generic, oral dose pharmaceuticals products, such as Phentermine HCl 37.5mg tablets, and 15mg and 30mg capsules for the treatment of bariatrics under Adipex-P brand; Phendimetrazine Tartrate 35mg tablets for bariatrics under the Bontril brand; Naltrexone HCl 50mg tablets for the treatment of pains under the Revia brand; and Isradipine 2.5mg and 5mg capsules for cardiovascular diseases. In addition, the company provides Trimipramine Maleate Immediate Release antidepressant capsules under the Surmontil brand; Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate, and Amphetamine Sulfate Immediate Release tablets under the Adderall brand, as well as Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate, Amphetamine Sulfate Extended Release capsules under the Adderall XR brand for central nervous system diseases; Dantrolene Sodium capsules for muscle relaxant under the Dantrium brand; SequestOX, an immediate release Oxycodone with sequestered Naltrexone; Loxapine Succinate capsules for treating antipsychotic under the Loxapine brand; Acetaminophen and Codeine Phosphate for the management of mild to moderate pain; and antibiotic products. Additionally, it manufactures controlled-release products on a contract basis for third parties in the areas of pain, allergy, bariatric, attention deficit, and infection. Further, the company is developing a range of abuse deterrent opioid products. The company was incorporated in 1997 and is headquartered in Northvale, New Jersey.

FAQ

Is ELTP financially healthy?

ELITE PHARMACEUTICALS INC /NV/'s Piotroski F-score is 6/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the safe zone.

Does ELTP pay a dividend?

No, ELITE PHARMACEUTICALS INC /NV/ does not currently pay a dividend.

How profitable is ELTP?

In FY2026, ELITE PHARMACEUTICALS INC /NV/ had a net margin of 30.1% and a return on equity of 45.4%.

What is ELTP's P/E ratio?

ELITE PHARMACEUTICALS INC /NV/'s trailing price-to-earnings (P/E) ratio is about 9.5×, based on its latest annual earnings.

Is ELTP a good stock to buy?

Stocktoria doesn't give buy or sell advice, but here is the data on ELITE PHARMACEUTICALS INC /NV/: a Piotroski F-score of 6/9, an Altman Z″ in the safe zone, a P/E of about 9.5×. Weigh these quality and valuation signals against your own goals.

Computed from company filings · US · as of 2026-03-31. Facts plus Stocktoria's own computed scores — not investment advice.